Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy

Marc Boutin

Marc Boutin, currently CEO of the National Health Council (NHC), brings 20 years of international leadership experience in health advocacy, policy and legislation. Throughout his professional career, he has focused on creating access to care through …

/by

Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

  • EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1
  • Chronic rhinosinusitis with nasal polyps is a debilitating condition for many patients, with symptoms including nasal blockage, difficulty breathing and sleeping, and loss of sense of smell, which reduce quality of life2–4
     
  • Approval builds on well-established efficacy and safety record of Xolair, which has over 1.3 million …
/by

Ensuring medicine supply to patients during COVID-19

Kalwe, India: staying on site to ensure leprosy drug production

Multidrug therapy (MDT) was a major breakthrough in the fight against leprosy and remains the cornerstone of the global leprosy elimination strategy. The Sandoz Kalwe site, located north of Mumbai on India’s west coast, manufactures and supplies MDT to the World Health Organization as part of the Novartis pledge to donate MDT medicines to eliminate leprosy. But in March, manufacturing and supplying MDT became a …

/by

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

  • Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1
     
  • ASCLEPIOS I and II demonstrated significant reductions in risk of relapses, confirmed disability worsening and profound reduction of active or new brain lesions1
     
  • The US Food and Drug Administration and European Medicines Agency are currently reviewing ofatumumab for the treatment of relapsing forms of multiple …
/by

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

  • Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate
     
  • Kymriah previously received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in r/r FL based on preliminary ELARA trial findings, reflecting the unmet need for additional treatment options for this cancer type
     
  • ELARA trial findings will be included in regulatory submissions, with filing in the US anticipated in 2021, and the EU following. Results will be …
/by

Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis

  • EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1
     
  • Moderate-to-severe psoriasis affects more than 350,000 children worldwide2, with the physical and psychological burden disrupting important formative years3
     
  • Cosentyx is a proven brand, supported by long-term five-year sustained efficacy and safety data across psoriasis, psoriatic arthritis ( …
/by

Collaborating to explore new gene regulation therapies

Novartis has entered into a research and development collaboration with Sangamo Therapeutics to explore potential gene regulation therapies for neurodevelopmental diseases. Proprietary technology platforms from both companies will be harnessed to facilitate progress toward potentially transformative treatments for life-long, debilitating conditions.

Sangamo is renowned for work on zinc finger proteins, which may be engineered to target select DNA sequences and switch specific genes on or off through the modulation of transcription. Novartis has deep experience with adeno-associated …

/by

Choice with Responsibility: Reimagining how we work

At Novartis, our people are our most valuable resource. We want everyone to feel able to be their best selves at work and at home, and we are committed to supporting and enabling them to be inspired, curious and unbossed. The global pandemic has accelerated our organizational need to explore new working models and our associates have expressed a strong desire for more flexibility in how, where and when they work. We believe we can create a future working model that optimizes both personal and business performance. Our journey toward that model is what we call Choice with Responsibility. …

/by

Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

  • Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care
     
  • Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months), compared to fulvestrant alone1,2
     
  • 334,000 people are diagnosed with advanced breast cancer worldwide each year, and approximately 40% of those with HR+/HER2- subtype have a PIK3CA mutation, which is associated with a poor prognosis3-12 …
/by

Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

  • Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe
     
  • Planned combined investment of more than EUR 150 million would include major innovative technology development and implementation for large-scale manufacture of active ingredients for leading penicillin products
     
  • Kundl manufacturing site in Austria is hub of last vertically integrated antibiotics production chain in Europe; Sandoz is #1 global supplier of generic antibiotics …
/by